Genetic testing aims to improve drug satisfaction in underserved communities
NCT ID NCT05141019
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving patients genetic test results early can help doctors choose better medications. About 492 adults with at least three prescriptions will be randomly assigned to get immediate or delayed genetic testing. The goal is to see if this approach improves how satisfied patients feel with their medications.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- pharmacogenetic testing
- What this could lead to
- If successful, this could show that preemptive genetic testing helps personalize medications and improve patient satisfaction, especially in underserved groups.
- What could go wrong
- This is an early-stage feasibility study with 492 participants, so results may not apply broadly. The main outcome is patient satisfaction, not clinical health improvements.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 492 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2022
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults \> 18 years of age * at least 3 active prescriptions documented within medical records * Experienced a change to an active prescription within the past 8 months, defined by: * Addition of a new medication * Change in the dose of a current medication * Diagnosis of any condition that could be treated with a medication that can be informed by the pharmacogenetic testing panel. This will likely include: * generalized depression or anxiety disorder * gastroesophageal reflux disorder * erosive esophagitis * gastric ulcer * acute coronary syndrome * chronic pain * surgery (orthopedic, gastrointestinal, cardiovascular etc.) * osteoarthritis * Dyslipidemia * Heart failure * Deep vein thrombosis * Atrial fibrillation * Moderate to severe trauma * stroke * hypercholesterolemia * conditions requiring chronic anticoagulation Exclusion Criteria: * Any history of previous pharmacogenetic testing * Any medical condition that would prohibit the ability to answer study questions * History of Allogenic stem cell or liver transplant * History of chronic kidney dialysis * Life expectancy less than 12 months
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pharmacogenetic testing are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UF Health at the University of Florida
Gainesville, Florida, 32610, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.